GutMicro Cancer Research Results

GutMicro, Gut Microbiota: Click to Expand ⟱
Source:
Type:
Gut microbiome may affect responses to numerous forms of cancer therapy.
The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology.


Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
4- Akk,    The Emerging Biotherapeutic Agent: Akkermansia
- Review, Var, NA
GutMicro↑,
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
3443- ALA,    Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention
- Review, Var, NA - Review, AD, NA
*antiOx↑, *ROS↓, *IronCh↑, *cognitive↑, *cardioP↓, AntiCan↑, *neuroP↑, *Inflam↓, *BioAv↓, *AntiAge↑, *Half-Life↓, *BioAv↝, other↝, EGFR↓, Akt↓, ROS↓, TumCCA↑, p27↑, PDH↑, Glycolysis↓, ROS↑, *eff↑, *memory↑, *motorD↑, *GutMicro↑,
5409- ASA,    Role of aspirin in cancer prevention
- Review, Var, NA
Imm↑, *Inflam↓, *AntiAg↑, *GutMicro↑, eff↑, TumMeta↓, angioG↓, Risk↓, Risk↓,
5571- B-Gluc,  immuno,    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
- Review, Var, NA
Imm↑, ChemoSen↑, LDL↑, GutMicro↑, TumCP↓, Apoptosis↑, angioG↓, QoL↑,
5577- B-Gluc,    Lentinan progress in inflammatory diseases and tumor diseases
- Review, Var, NA - Review, IBD, NA
AntiTum↑, GutMicro↑, *Inflam↓, *TNF-α↓, *NF-kB↓, ChemoSen↑, OS↑, Imm↑, IL6↓, ERK↓, MAPK↓, *antiOx↑, eff↑,
2605- Ba,  BA,    Potential therapeutic effects of baicalin and baicalein
- Review, Var, NA - Review, Stroke, NA - Review, IBD, NA - Review, Arthritis, NA - Review, AD, NA - Review, Park, NA
cardioP↑, Inflam↓, cognitive↑, *hepatoP↑, *ROS?, *SOD↑, *GSH↑, *MMP↑, *GutMicro↑, ChemoSen↑, *TNF-α↓, *IL10↑, *IL6↓, *eff↑, *ROS↓, *COX2↓, *NF-kB↓, *STAT3↓, *PGE2↓, *MPO↓, *IL1β↓, *MMP2↓, *MMP9↓, *β-Amyloid↓, *neuroP↑, *Dose↝, *BioAv↝, *BioAv↝, *BBB↑, *BDNF↑,
5628- Bif,  immuno,    Bifidobacterium modulation of tumor immunotherapy and its mechanism
- Review, Var, NA
Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,
5629- Bif,  ProBio,    Gut microbiota shapes cancer immunotherapy responses
- Review, Var, NA
eff↑, DCells↑, CD8+↑, eff↑, AntiTum↑, other↑, selectivity↑, GutMicro↑,
2776- Bos,    Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities
- Review, Var, NA
*5LO↓, *TNF-α↓, *MMP3↓, *COX1↓, *COX2↓, *PGE2↓, *Th2↑, *Catalase↑, *SOD↑, *NO↑, *PGE2↑, *IL1β↓, *IL6↓, *Th1 response↓, *Th2↑, *iNOS↓, *NO↓, *p‑JNK↓, *p38↓, GutMicro↑, p‑Akt↓, GSK‐3β↓, cycD1/CCND1↓, Akt↓, STAT3↓, CSCs↓, AR↓, P21↑, DR5↑, CHOP↑, Casp3↑, Casp8↑, cl‑PARP↑, DNAdam↑, p‑RB1↓, FOXM1↓, TOP2↓, CDC25↓, p‑CDK1↓, p‑ERK↓, MMP9↓, VEGF↓, angioG↓, ROS↑, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, ChemoSen↑, SOX9↓, ER Stress↑, GRP78/BiP↑, cal2↓, AMPK↓, mTOR↓, ROS↓,
5744- Buty,  PacT,    Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction
- in-vivo, Var, NA
chemoP↑, neuroP↑, Inflam↓, GutMicro↑, *ROS↓, Dose↝,
5743- Buty,    Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status
- Review, Var, NA
*GutMicro↑, *other↑, *Inflam↓, *ROS↓, AntiCan↑, HCAR2↑, HDAC↓,
5739- Buty,    Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)
- Review, Var, NA
GutMicro↑, *Inflam↓, *IL6↓, *TNF-α↓, *IL17↓, *IL10↑, *ROS↝, COX2↓, NLRP3↓, Imm↑, HDAC↓, TumCCA↑, Apoptosis↑, ROS↑, Casp↑, mtDam↑, Cyt‑c↑, eff↑, chemoP↑, ChemoSen↑, eff↑, RadioS↑, HCAR2↑,
5859- CAP,    Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain?
- Review, Var, NA
*TRPV1↑, *Ca+2↑, *Na+↑, *UCPs↑, *SIRT1↑, *PPARγ↑, *Inflam↓, *lipid-P↑, *IL6↓, *TNF-α↓, *NF-kB↓, *p‑Akt↑, *NRF2↑, *HO-1↑, *ROS↑, *GutMicro↑,
6016- CGA,    Coffee Chlorogenic Acids Incorporation for Bioactivity Enhancement of Foods: A Review
- Review, Var, NA - Review, AD, NA - Review, Diabetic, NA
antiOx↑, *Bacteria↓, AntiCan↑, *Inflam↓, *cardioP↑, *AntiDiabetic↑, *GutMicro↑, *eff↑, *eff↑, *ROS↓, *IronCh↑, *neuroP↑, *AChE↓, *BChE↓, *chemoPv↑, *BioAv⇅,
1856- dietFMD,  immuno,    Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review
- Review, Var, NA
GutMicro↑,
1863- dietFMD,  Chemo,    Effect of fasting on cancer: A narrative review of scientific evidence
- Review, Var, NA
eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,
1773- GA,    Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action
- Review, Var, NA
antiOx↑, AntiCan↑, Inflam↑, GutMicro↑, BioAv↝, BioAv↓, BioAv↑, TumMeta↓,
2523- H2,    Prospects of molecular hydrogen in cancer prevention and treatment
- Review, Var, NA
ROS↓, TumCP↓, TumMeta↓, AntiTum↑, GutMicro↑, Inflam↓, OS↑, radioP↑, selectivity↑, SOD↑, IL1β↑, IL8↑, TNF-α↑, neuroP↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
4800- Lyco,    Recent insights on pharmacological potential of lycopene and its nanoformulations: an emerging paradigm towards improvement of human health
- Review, Var, NA
*antiOx↑, Keap1↝, NF-kB↝, NRF2↝, PI3K↝, Akt↝, mTOR↝, *GutMicro↑,
3929- PTS,    New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects
- Review, Var, NA - Review, Arthritis, NA
*NRF2↑, *BioAv↑, *ROS↓, *Inflam↓, *HO-1↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *hepatoP↑, *neuroP↑, *iNOS↓, *COX2↓, TumMeta↓, SOD2↓, ROS↑, TumCI↓, TumCG↓, HDAC1↓, PTEN↑, BP↓, *GutMicro↑,
3001- RosA,    Therapeutic Potential of Rosmarinic Acid: A Comprehensive Review
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, Inflam↓, *antiOx↑, *AntiAge↑, *ROS↓, BioAv↑, Dose↝, NRF2↑, P-gp↑, ATP↑, MMPs↓, cl‑PARP↓, Hif1a↓, GlucoseCon↓, lactateProd↓, Warburg↓, TNF-α↓, COX2↓, IL6↓, HDAC2↓, GSH↑, ROS↓, ChemoSen↑, *BG↓, *IL1β↓, *TNF-α↓, *IL6↓, *p‑JNK↓, *p38↓, *Catalase↑, *SOD↑, *GSTs↑, *VitC↑, *VitE↑, *GSH↑, *GutMicro↑, *cardioP↑, *ROS↓, *MMP↓, *lipid-P↓, *NRF2↑, *hepatoP↑, *neuroP↑, *P450↑, *HO-1↑, *AntiAge↑, *motorD↓,
4609- SeNPs,    Physiological Benefits of Novel Selenium Delivery via Nanoparticles
- Review, Var, NA - Review, IBD, NA - Review, Diabetic, NA
*selenoP↑, Risk↓, AntiCan↑, ROS↑, *Dose↝, *toxicity↓, *BioAv↑, *GutMicro↑, *other↓,
4498- SSE,    Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
*Imm↑, *GutMicro↑, *BioAv↑, *Risk↓, *Dose↝, Risk↓, *CRP↓, *GPx↓, *Inflam↓, *selenoP↑, *Dose↝, *ROS↓, *MDA↓, *SOD↑, *GPx↑, *IL1↓, *MCP1↓, *IL6↓, *TNF-α↓, Risk↓, *neuroP↑, *memory↑,
4497- SSE,    Selenium and inflammatory bowel disease
- Review, Var, NA - Review, IBD, NA
*GutMicro↑, *selenoP↑, *Inflam↓, Risk↓, *NF-kB↓, *ROS↓,
4494- SSE,    Advances in the study of selenium and human intestinal bacteria
- Review, IBD, NA - Review, Var, NA
*Risk↓, OS↑, *CRP↓, *GPx↑, *Inflam↓, *ROS↓, *GutMicro↑, *selenoP↑, *other↓,
5934- TV,    Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties
- Review, Var, NA
*Inflam↓, *antiOx↑, *Bacteria↓, AntiTum↑, *toxicity∅, *IBI↑, *ZO-1↑, *OCLN↑, *COX1↑, *TLR4↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *TAC↑, *NRF2↑, *GutMicro↑,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,

Showing Research Papers: 1 to 30 of 30

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 30

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↓, 1,   GSH↓, 1,   GSH↑, 1,   HO-1↓, 1,   Keap1↝, 1,   NRF2↓, 1,   NRF2↑, 1,   NRF2↝, 1,   OXPHOS↑, 1,   ROS↓, 5,   ROS↑, 9,   SOD↓, 1,   SOD↑, 1,   SOD2↓, 1,   Trx1↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↑, 2,   CDC2↓, 1,   CDC25↓, 1,   Insulin↓, 1,   mitResp↓, 1,   MMP↓, 2,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↓, 1,   cMyc↑, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   lactateProd↓, 1,   LDL↑, 1,   PDH↑, 1,   SIRT1↑, 2,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 5,   Akt↝, 1,   p‑Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 6,   BAX↑, 2,   Bcl-2↓, 3,   Casp↑, 3,   Casp12↑, 1,   Casp3↑, 3,   Casp8↑, 2,   Casp9↑, 2,   proCasp9↓, 1,   Chk2↓, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 2,   Fas↑, 1,   hTERT/TERT↓, 1,   ICAD↓, 1,   iNOS↓, 1,   MAPK↓, 3,   MAPK↑, 1,   MDM2↓, 1,   p27↑, 1,   p38↑, 2,   survivin↓, 2,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

HCAR2↑, 2,   SOX9↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 1,   Beclin-1↑, 2,   BNIP3↑, 1,   LAMP2↑, 1,   LC3II↑, 1,   p62↓, 1,   p62↑, 1,   TumAuto↝, 1,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   CHK1↓, 2,   DNAdam↑, 3,   P53↑, 5,   cl‑PARP↓, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

p‑CDK1↓, 1,   CDK2↓, 2,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 2,   E2Fs↑, 1,   P21↑, 3,   p‑RB1↓, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 2,   FOXM1↓, 1,   FOXO1↑, 1,   GSK‐3β↓, 1,   HDAC↓, 3,   HDAC1↓, 1,   HDAC2↓, 1,   IGF-1↓, 1,   mTOR↓, 2,   mTOR↝, 1,   NOTCH↓, 1,   PI3K↓, 2,   PI3K↝, 1,   PTEN↑, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   STAT5↓, 1,   TOP2↓, 1,   TumCG↓, 2,  

Migration ⓘ

cal2↓, 1,   E-cadherin↑, 2,   FAK↓, 1,   p‑FAK↓, 1,   MMP2↓, 1,   MMP9↓, 2,   MMPs↓, 1,   N-cadherin↓, 2,   Snail↓, 1,   Treg lymp↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 5,   TumMeta↓, 7,   Twist↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   angioG↑, 1,   EGFR↓, 1,   p‑EGFR↓, 1,   Hif1a↓, 3,   VEGF↓, 4,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

P-gp↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   DCells↑, 1,   HCAR2↑, 2,   IL1↓, 1,   IL1β↑, 1,   IL6↓, 3,   IL8↓, 1,   IL8↑, 1,   Imm↑, 6,   Inflam↓, 4,   Inflam↑, 1,   M2 MC↓, 1,   NF-kB↓, 2,   NF-kB↝, 1,   TNF-α↓, 2,   TNF-α↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 2,   ChemoSen↑, 10,   Dose↝, 3,   eff↓, 1,   eff↑, 9,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 1,   BG↓, 1,   BP↓, 1,   BRCA1↓, 1,   EGFR↓, 1,   p‑EGFR↓, 1,   FOXM1↓, 1,   GutMicro↑, 16,   hTERT/TERT↓, 1,   IL6↓, 3,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 6,   AntiTum↑, 5,   cardioP↑, 2,   chemoP↑, 4,   ChemoSideEff↓, 1,   cognitive↑, 1,   neuroP↑, 2,   OS↑, 4,   QoL↑, 1,   radioP↑, 1,   Risk↓, 7,  

Infection & Microbiome ⓘ

CD8+↑, 2,  
Total Targets: 188

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 8,   Catalase↑, 4,   GPx↓, 1,   GPx↑, 4,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 3,   HO-1↑, 3,   Keap1↓, 1,   lipid-P↓, 5,   lipid-P↑, 1,   MDA↓, 2,   MPO↓, 2,   NRF2↑, 6,   ROS?, 1,   ROS↓, 16,   ROS↑, 1,   ROS↝, 1,   selenoP↑, 4,   SOD↑, 8,   TAC↑, 1,   TBARS↓, 1,   UCPs↑, 1,   VitC↑, 1,   VitE↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   H2S↑, 1,   LDH↓, 2,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↑, 1,   iNOS↓, 3,   p‑JNK↓, 2,   p38↓, 2,   TRPV1↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 2,   other↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,   STAT3↓, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   Ca+2↑, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   Na+↑, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 3,   NO↑, 1,  

Barriers & Transport ⓘ

BBB↑, 3,   IBI↑, 1,   Na+↑, 1,   OCLN↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX1↑, 1,   COX2↓, 4,   CRP↓, 2,   IL1↓, 1,   IL10↑, 2,   IL17↓, 1,   IL1β↓, 4,   IL6↓, 8,   Imm↑, 1,   Inflam↓, 14,   MCP1↓, 1,   NF-kB↓, 6,   PGE2↓, 3,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR4↓, 1,   TNF-α↓, 10,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BChE↓, 1,   BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   β-Amyloid↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv⇅, 1,   BioAv↝, 3,   Dose↝, 4,   eff↑, 5,   Half-Life↓, 1,   Half-Life↝, 1,   P450↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BG↓, 1,   BP↓, 1,   creat↓, 1,   CRP↓, 2,   GutMicro↑, 15,   IL6↓, 8,   LDH↓, 2,  

Functional Outcomes ⓘ

AntiAge↑, 3,   AntiDiabetic↑, 1,   cardioP↓, 1,   cardioP↑, 4,   chemoPv↑, 1,   cognitive↑, 3,   hepatoP↑, 4,   memory↑, 3,   motorD↓, 1,   motorD↑, 1,   neuroP↑, 10,   Risk↓, 2,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 2,  
Total Targets: 115

Scientific Paper Hit Count for: GutMicro, Gut Microbiota
3 immunotherapy
3 Butyrate
3 Selenite (Sodium)
2 beta-glucans
2 Bifidobacterium
2 diet FMD Fasting Mimicking Diet
1 Akkermansia
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 Aspirin -acetylsalicylic acid
1 Baicalein
1 Baicalin
1 probiotics
1 Boswellia (frankincense)
1 Paclitaxel
1 Capsaicin
1 Chlorogenic acid
1 Chemotherapy
1 Gallic acid
1 Hydrogen Gas
1 Luteolin
1 Lycopene
1 Pterostilbene
1 Rosmarinic acid
1 Selenium NanoParticles
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:350  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page